DiaSorin S.p.A. (0GZX.L)

137.87 +3.48 (+2.59%) At close: 05:10PM BST

DiaSorin S.p.A.

Via Crescentino
Saluggia, VC 13040
Italy
39 01 614871
https://diasoringroup.com/en

Sector(s): 
Industry: 
Full-time employees: 3,184

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Carlo Rosa	CEO, GM & Executive Director	1.75M	N/A	1966
Dr. Chen Menachem Even	Chief Commercial Officer, Senior Corporate VP of Commercial Operations & Executive Director	857.25k	N/A	1963
Mr. Piergiorgio Pedron	Senior Corporate VP, CFO & Corporate Accounting Documents Officer	N/A	N/A	1971
Mr. Fabrizio Piercarlo Bonelli	Corporate VP & Chief Technology Officer	N/A	N/A	N/A
Dr. Riccardo Fava	Corporate Vice President of Communication & Investor Relations	N/A	N/A	N/A
Mr. Ulisse Spada	Corporate VP, Head of the Legal Department, Secretary & General Counsel	N/A	N/A	N/A
Mr. Stefano Ronchi	Senior Corporate Vice President of Human Resources	N/A	N/A	1960
Mr. Angelo Rago	President of Luminex Corporation	N/A	N/A	1963

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Corporate governance

DiaSorin S.p.A.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.